2022
DOI: 10.1016/j.esmoop.2022.100404
|View full text |Cite
|
Sign up to set email alerts
|

Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
87
0
5

Year Published

2022
2022
2024
2024

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 107 publications
(92 citation statements)
references
References 59 publications
0
87
0
5
Order By: Relevance
“… 13 Increased knowledge of ILD/pneumonitis and implementation of ILD/pneumonitis monitoring, diagnosis, and management guidelines may explain why there were no grade 4 or 5 events since ILD/pneumonitis events may have been identified and treated early before they progressed. 23 DESTINY-Breast03 investigated T-DXd as an earlier line of therapy than the trials included in this pooled analysis [median prior lines of therapy, 4 (range, 1-27)], which implies that perhaps there is a lower rate of ILD/pneumonitis in patients who are less heavily pretreated, although line of therapy was not identified as a potential factor of interest in the multivariate analysis reported here. The present analysis reflects a heavily pretreated population overall, including data from multiple tumor types, which may also partially explain differences in the rates of ILD/pneumonitis observed between the pooled analysis and DESTINY-Breast03.…”
Section: Discussionmentioning
confidence: 99%
“… 13 Increased knowledge of ILD/pneumonitis and implementation of ILD/pneumonitis monitoring, diagnosis, and management guidelines may explain why there were no grade 4 or 5 events since ILD/pneumonitis events may have been identified and treated early before they progressed. 23 DESTINY-Breast03 investigated T-DXd as an earlier line of therapy than the trials included in this pooled analysis [median prior lines of therapy, 4 (range, 1-27)], which implies that perhaps there is a lower rate of ILD/pneumonitis in patients who are less heavily pretreated, although line of therapy was not identified as a potential factor of interest in the multivariate analysis reported here. The present analysis reflects a heavily pretreated population overall, including data from multiple tumor types, which may also partially explain differences in the rates of ILD/pneumonitis observed between the pooled analysis and DESTINY-Breast03.…”
Section: Discussionmentioning
confidence: 99%
“…
Figure 2 Management of ILD/pneumonitis. 20 , 59 , 61 , 62 The ‘Manage ILD/P’ portion of this figure is from Figure 3 of Swain SM, Nishino M, Lancaster LH, et al. Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and management.
…”
Section: Management Of T-dxd-related Aes Of Interestmentioning
confidence: 99%
“…8,16,20 It is of the utmost importance to monitor and assess patients for ILD/pneumonitis to reduce the risk of fatal outcomes (Figure 2). 59,61 In 2019, guidelines for the management and monitoring of T-DXd-related ILD/pneumonitis were published and incorporated into clinical trials of T-DXd 6 ; these were updated in 2021. 20 These guidelines stress the importance of proactive management and monitoring to help identify and treat ILD/pneumonitis as effectively as possible; the guidelines provide more details around steroid dosing, duration, and timing of taper for better management (Figure 2).…”
Section: Ild/pneumonitismentioning
confidence: 99%
“…According to the latest expert opinion, this case was diagnosed as a grade 4 (very severe) ICI‐ILD. 24 It was recommended to use mechanical ventilation, steroid therapy (2 mg/kg/day intravenous prednisolone or equivalent) and even intravenous immunoglobulins. We have implemented these treatments in compliance with the expert opinion.…”
Section: Discussionmentioning
confidence: 99%